China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $5.08K invested in China SXT Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
75% less funds holding
Funds holding: 4 → 1 (-3)
83% less capital invested
Capital invested by funds: $30K → $5.08K (-$24.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$9K |
| 2 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$7.93K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.14K |
| 4 |
JP Morgan Chase
New York
|
-$274 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of Montreal
Toronto,
Ontario, Canada
| $5.08K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $4 | -$4.14K | -7 | Closed |
|
|
BBA
3
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$7.93K | -13 | Closed |
|
|
GCP
4
GSA Capital Partners
London,
United Kingdom
| – | -$9K | -10 | Closed |
|
|
5
JP Morgan Chase
New York
| – | -$274 | – | – |
|
SXTC Hedge Fund Activity: Q4 2024 in Review
1 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q4 2024, worth a combined $5.08K — down 83% from $30K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SXTC and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was GSA Capital Partners, exiting entirely with an estimated $9K sold.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q4 2024, down from 4 in Q3 2024.
- Funds reported $5.08K of China SXT Pharmaceuticals stock for Q4 2024, down 83% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q4 2024 and 3 closed out, a net change of -3 holders.
- The largest China SXT Pharmaceuticals seller in Q4 2024 was GSA Capital Partners, an estimated $9K sold.
Based on aggregated 13F filings for Q4 2024.